Every letter we have printed

Time of day matters for several of the analytes discussed in this context, and a series collected at different hours is a series with a systematic wobble in it. Same laboratory, same time, same conditions is worth more than any additional test.

Fasting status changes several common analytes substantially, and self-arranged testing frequently records it wrongly or not at all. It is the single most common preventable source of a surprising result.

Trend beats absolute value for almost everything in an organ panel, and a single report cannot show a trend. The most useful thing anybody can do is keep every result they have ever had in one place.

Blinding a withdrawal is harder than blinding an initiation, for reasons that are obvious once stated: the effects being withdrawn are perceptible. Any withdrawal trial reporting successful blinding should be asked how it was assessed.

Regain curves are usually plotted from the point of withdrawal, which flatters them. Plotted from baseline they show something else entirely, and the choice of origin is a presentational decision with a large effect on the impression.

I stopped eight months ago after reaching a weight I was happy with, and I have regained four of the twenty-two kilograms I lost. Every article I read told me to expect two-thirds back. I am not complaining, but I would like to know whether I am unusual or whether the two-thirds figure was always a mean concealing an enormous range.

I run a laboratory that issues these reports and I read your criticism as fair. What we control is the document; what happens to our logo afterwards is outside our sight entirely. We would welcome a convention that let us take it back.

A translation problem worth noting: many buyers in this market read these pages in a second language, and an image survives translation where a paragraph of qualification does not. The badge is therefore doing more work for exactly the readers least able to interrogate it.

Nobody has defined what custody means in a market where the buyer is an individual and the laboratory is on another continent. Importing the phrase from clinical practice without importing the institutions has produced a word with no local meaning.

Photographs are a poor substitute for a signature and a good substitute for nothing. Vial, label, seal, packaging, with a timestamp — five minutes of work that has settled every dispute I have been involved in.

Your series has not yet addressed what a buyer should do with a single blind result that disagrees with a supplier’s certificate. The honest answer is very little, and saying so would be more useful than another round of methodological argument.

You describe blind purchasing as the gold standard. It is the minimum standard. The gold standard is blind purchasing, repeated, with retained samples, published in full including the dull results, and nothing in this market comes close to that.

The submitter-pays problem is real and I think you overstate it slightly. A laboratory that shades results towards its customers loses the only asset it has the moment a second laboratory disagrees in public. The incentive to please the payer is immediate; the incentive to be right is larger and slower.

I keep a bound notebook for submissions: date, molecule, lot, weight sent, courier, tracking, laboratory, report number. It is unglamorous, it takes two minutes an entry, and it has made me the only party in several conversations with an actual record.

Custody documents are only as good as the willingness to produce them later. A record kept privately and never shown is a comfort rather than a control, and the difference shows up the first time somebody asks.

Most of the management advice in circulation has no trial behind it and is drawn from clinical experience, which is a legitimate source that should be labelled as one. Your article does label it, and that alone puts it ahead of the material readers usually find. This is not medical advice.

Hydration advice is given universally and is more important where symptoms include losses, which is not everybody. Blanket recommendations tend to be repeated past the point where they apply, and specifying the situation would improve them.

Nobody publishes the distribution, only the proportion. Whether effects are mild across most of a population or severe in a small part of it is the question a reader has, and an incidence figure cannot answer it either way.

The figures that circulate are cumulative incidence over a whole trial, and they are read as though they described how somebody feels in a given week. Those are very different quantities, and the second is much smaller than the first. Your table separating them is the most useful thing published on this in a while.

Any transposition of two residues preserves the intact mass exactly. So does a substitution that swaps one residue for another of the same composition. The set of molecules consistent with a given mass is not small, and describing a mass match as identity confirmation makes a claim about that whole set.

Tandem mass spectrometry with sequence coverage stated as a percentage is the thing to ask for, and the percentage is the part that gets omitted. Sixty per cent coverage on a thirty-residue peptide leaves twelve residues unverified, and where those twelve sit determines whether the result means anything.

I would add one omission to your six lines: the date and nature of the last calibration. A parts-per-million figure from an instrument last calibrated a fortnight ago is a different claim from one calibrated that morning with an internal standard.

Endotoxin is invisible to everything you describe and to everything most buyers commission. It is not a purity question, it is not an identity question, and it is not answered by any instrument in this article. Saying so plainly is worth a paragraph in its own right.

A word of appreciation for the practice of quoting the sample size beside every figure. It has quietly deflated a good deal of what I used to believe.

The point I would press is documentation. Whatever schedule is followed, writing down the dose, the date and what happened turns an anecdote into a small dataset. Most of the confusion I hear about comes from people who cannot reconstruct what they did.

An approved schedule is a regulatory artefact reflecting what was submitted and what was studied, and it is read as a statement about what is optimal. Those are different things and the gap between them is not evidence of anything.

A badge is a statement about a moment. It says a sample submitted on a particular day met a particular threshold, and it is displayed indefinitely on a page selling material made months later. Nothing dishonest has happened and the reader has still been told something untrue.

The graphic language is borrowed from certification marks in other industries, where a mark means an audited and continuing arrangement. Here it means a single paid determination. The visual grammar has been imported and the meaning behind it has not.

I submitted a vial to one of these services last year, got a result three points below what the vendor advertised, and did not know what to do with it. Your article explains why: I had one measurement on one vial, no method comparison, and no way to know if my vial was representative. I still do not know what to do with it, but I understand the shape of not knowing.

Adherence is the variable that does most of the work and it is the one least often reported. A programme that is performed twice a week for a year beats a better programme abandoned in March, and the trial literature systematically studies the second kind.

Nothing in this area has been studied in the population that most reads about it, which is people acquiring material outside a clinical setting and training without supervision. Every figure is a read-across and should be labelled as one.

Where a panel is chosen from a menu, people select the analytes they have read about, which produces panels that are wide in the fashionable areas and empty elsewhere. A published example panel with the reasoning would be a useful reference entry.

Baseline before rather than after is the single most valuable thing anybody can do, and it is the one thing that cannot be recovered later. A series without a starting point is much harder to read.

The date I want is not the date the document was issued but the date the injection was made. They can differ by months, and a certificate issued today from a determination performed last year describes a material that has since sat in a warehouse through a summer.

Quantity tested against quantity released deserves a line. A determination on a hundred milligrams drawn from a five-kilogram campaign is a different kind of evidence from a determination on a vial drawn from a hundred-vial fill, and the certificate reports both in the same font.

The lot number should appear in a form that can be matched to the vial without interpretation. Half the certificates I hold carry a batch code with a different number of digits from the one printed on the label, and reconciling them is guesswork the buyer should not be doing.

The most useful sentence in the piece is the one saying a bad document is not a bad product. I have spent two years on forums watching people conclude the opposite from a missing signature block, and it has made the whole conversation about honesty rather than about paperwork.

The pathways that matter for potency and the pathways that matter for immunogenicity are not the same set, and only the first is discussed in this market at all. The second is a proper research question and not a topic for speculation.

Sequence-based prediction tools for susceptible motifs exist and are freely available. Anybody arguing about storage for a specific molecule could spend ten minutes establishing which pathways are even plausible for it.

A phase-change pack and a frozen gel pack behave completely differently and are both described as cold packs. The first holds a temperature and the second holds a very low temperature briefly and then does nothing.